Pharma Penny Stock Under Rs 50 In Focus As Company Enters Into Technology Transfer Agreement with Uttaranchal University
The stock gave multibagger returns of 662 per cent from its 52-week low of Rs 5.82 per share.
On Monday, shares of Sudarshan Pharma Industries Ltd plunged 2 per cent to Rs 43.16 per share from its previous closing of Rs 44.04 per share. The stock’s 52-week high is Rs 53.50 per share while its 52-week low is Rs 5.82 per share.
Sudarshan Pharma Industries Limited informed that it has entered into a Technology Transfer Agreement (Agreement) dated January 24, 2025, with Uttaranchal University. This Agreement grants the Company the exclusive rights, interest, and ownership of Indian Patent No. 202111029005 (relating to the Preparation of Bioplastic from Stubble of Rice, Aloe Vera Waste, PVA and Glycerol Plasticizer). The Agreement is valid for a period of five years, commencing on January 24, 2025.
Earlier, The Company entered into a 5-year Rent Agreement with Daundi Biological Private Limited to establish a new R&D formulation centre in Dehradun, commencing operations in March 2025. Additionally, the Board has approved the acquisition of 100 per cent of Cibachem General Trading L.L.C., Dubai, for Rs 25,00,000, aiming to expand the Company's customer base in the Middle East. Cibachem is a general trading company, and this acquisition, not considered a related party transaction, is subject to RBI approval and expected to be completed by March 31, 2025.
DSIJ’s ‘Micro Marvel' service recommends micro-cap stocks with the potential to grow multifold in long run. If this interests you, do download the service details here.
About the Company
Sudarshan Pharma Industries Limited (SPIL), established in 2008 and headquartered in Mumbai, is a prominent contract manufacturer of generic formulations. Operating across diverse segments, including speciality chemicals, intermediates, APIs, pharmaceutical and formulation generics, and bulk supply, SPIL caters to a wide range of institutions and healthcare organizations. Beyond its contract manufacturing services, SPIL has ventured into branded products through its Vimac Healthcare division. A significant portion of its product portfolio, consisting of 56 out of 96 items, is registered under the "R" trademark. Furthermore, SPIL collaborates with renowned Indian companies and institutional clients, offering contract manufacturing services for pharmaceutical formulations and medicines.
On November 22, 2023, the shares of the company ex-traded sub-division /stock split of the company’s 1 (one) equity share having a face value of R 10 each fully paid-up, into 10 equity shares of the company having a face value of Re 1 each fully paid-up.
The company has a market cap of over Rs 1,000 crore and has delivered good profit growth of 37 per cent CAGR over the last 5 years. The stock gave multibagger returns of 662 per cent from its 52-week low of Rs 5.82 per share. Investors should keep an eye on this micro-cap stock.
Disclaimer: The article is for informational purposes only and not investment advice.